Related references
Note: Only part of the references are listed.Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma
Yang Bai et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2021)
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
Federica Costa et al.
FRONTIERS IN IMMUNOLOGY (2021)
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
Norihiro Watanabe et al.
MOLECULAR THERAPY (2021)
Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma
Wen Lei et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
Jessica Wenthe et al.
CANCER GENE THERAPY (2020)
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
Nandakumar Packiriswamy et al.
LEUKEMIA (2020)
Cancer immunoediting and immune dysregulation in multiple myeloma
Kyohei Nakamura et al.
BLOOD (2020)
Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
Zong Sheng Guo et al.
BIOMEDICINES (2020)
Oncolytic viruses for cancer immunotherapy
Otto Hemminki et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy
Valentina Marchica et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Multiple myeloma current treatment algorithms
S. Vincent Rajkumar et al.
BLOOD CANCER JOURNAL (2020)
Harnessing viruses to target tumours
Carolyn Brown
NATURE (2020)
Novel targets for the treatment of relapsing multiple myeloma
Nicola Giuliani et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Complement in Motion: The Evolution of CD46 from a Complement Regulator to an Orchestrator of Normal Cell Physiology
M. Kathryn Liszewski et al.
JOURNAL OF IMMUNOLOGY (2019)
Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development
Nadishka Jayawardena et al.
ONCOLYTIC VIROTHERAPY (2019)
Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model
Chandini M. Thirukkumaran et al.
BLOOD ADVANCES (2019)
JAM-A as a prognostic factor and new therapeutic target in multiple myeloma
A. G. Solimando et al.
LEUKEMIA (2018)
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy
K. R. Kelly et al.
LEUKEMIA (2018)
Oncolytic viruses and immunity
Shyambabu Chaurasiya et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Oncolytic Viruses for Multiple Myeloma Therapy
Christine M. Calton et al.
CANCERS (2018)
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Sonia Guedan et al.
FRONTIERS IN IMMUNOLOGY (2018)
Measles virus: Background and oncolytic virotherapy
Sankhajit Bhattacharjee et al.
BIOCHEMISTRY AND BIOPHYSICS REPORTS (2018)
Integrating oncolytic viruses in combination cancer immunotherapy
Praveen K. Bommareddy et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Potential of oncolytic viruses in the treatment of multiple myeloma
Eric Bartee
ONCOLYTIC VIROTHERAPY (2018)
Systemic virotherapy for multiple myeloma
Stefania Oliva et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update
Sebastien A. Felt et al.
JOURNAL OF GENERAL VIROLOGY (2017)
Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma
A. Dispenzieri et al.
LEUKEMIA (2017)
Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
Daniel E. Meyers et al.
BLOOD CANCER JOURNAL (2017)
Oncolytic Viruses in Cancer Treatment A Review
Sean E. Lawler et al.
JAMA ONCOLOGY (2017)
Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
Anwen Howells et al.
FRONTIERS IN ONCOLOGY (2017)
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Saurabh Chhabra
PHARMACEUTICALS (2017)
News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1
Bart van de Sluis et al.
CURRENT OPINION IN LIPIDOLOGY (2017)
Myeloid-derived suppressor cells: The green light for myeloma immune escape
Ehsan Malek et al.
BLOOD REVIEWS (2016)
Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells
Mee Y. Bartee et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells
Daniel W. Sherbenou et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma
Andrew Stiff et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Multiple myeloma epidemiology and survival: A unique malignancy
Dickran Kazandjian
SEMINARS IN ONCOLOGY (2016)
Measles
Paul A. Rota et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma
Wen Lei et al.
SCIENTIFIC REPORTS (2016)
The Role of Immunotherapy in Multiple Myeloma
Mehmet Kocoglu et al.
PHARMACEUTICALS (2016)
Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells
Nancy Y. Villa et al.
BLOOD (2015)
Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
S. Yousef et al.
BLOOD CANCER JOURNAL (2015)
Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
Kevin R. Kelly et al.
ONCOTARGET (2015)
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma
Katherine M. Dunlap et al.
ONCOLYTIC VIROTHERAPY (2015)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
Douglas W. Sborov et al.
CLINICAL CANCER RESEARCH (2014)
Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
William Wold et al.
CURRENT GENE THERAPY (2014)
Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy
Stephen J. Russell et al.
MAYO CLINIC PROCEEDINGS (2014)
Immunological Dysregulation in Multiple Myeloma Microenvironment
Alessandra Romano et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Applications of coxsackievirus A21 in oncology
Stephen Bradley et al.
ONCOLYTIC VIROTHERAPY (2014)
Reovirus modulates autophagy during oncolysis of multiple myeloma
Chandini M. Thirukkumaran et al.
AUTOPHAGY (2013)
Oncolytic Virotherapy
Daniel Y. Sze et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2013)
LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus
Danit Finkelshtein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β
S. Naik et al.
CANCER GENE THERAPY (2012)
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer
Eric Hastie et al.
JOURNAL OF GENERAL VIROLOGY (2012)
Curative one-shot systemic virotherapy in murine myeloma
S. Naik et al.
LEUKEMIA (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma
K. R. Kelly et al.
ONCOGENE (2012)
Oncolytic Virotherapy for Hematological Malignancies
Swarna Bais et al.
ADVANCES IN VIROLOGY (2012)
Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future
Chandini M. Thirukkumaran et al.
BONE MARROW RESEARCH (2011)
Infection and Killing of Multiple Myeloma by Adenoviruses
Julien S. Senac et al.
HUMAN GENE THERAPY (2010)
Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma
Kah-Whye Peng et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Junctional Adhesion Molecule-A Is Required for Hematogenous Dissemination of Reovirus
Annukka A. R. Antar et al.
CELL HOST & MICROBE (2009)
Growth Inhibition of Human Multiple Myeloma Cells by an Oncolytic Adenovirus Carrying the CD40 Ligand Transgene
Margret S. Fernandes et al.
CLINICAL CANCER RESEARCH (2009)
A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients
J-L Li et al.
GENE THERAPY (2009)
Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy
Candice Willmon et al.
MOLECULAR THERAPY (2009)
Oncolytic viruses: a novel form of immunotherapy
Robin J. Prestwich et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth
A. Munguia et al.
GENE THERAPY (2008)
Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus
H. Deng et al.
LEUKEMIA (2008)
Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene
Apollina Goel et al.
BLOOD (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma
Gough G. Au et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies
H. T. Ong et al.
GENE THERAPY (2007)
Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy
Ianko D. Iankov et al.
MOLECULAR THERAPY (2007)
History of oncolytic viruses: Genesis to genetic engineering
Elizabeth Kelly et al.
MOLECULAR THERAPY (2007)
Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo
R. Schmidmaier et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2006)
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells
Hooi Tin Ong et al.
EXPERIMENTAL HEMATOLOGY (2006)
To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control
I Mohr
ONCOGENE (2005)
Characteristics in the epidemiology of bovine viral diarrhea virus (BVDV) of relevance to control
A Lindberg et al.
PREVENTIVE VETERINARY MEDICINE (2005)
CD46 is a cellular receptor for bovine viral diarrhea virus
K Maurer et al.
JOURNAL OF VIROLOGY (2004)
The JAM family of junctional adhesion molecules
G Bazzoni
CURRENT OPINION IN CELL BIOLOGY (2003)
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
M Ratta et al.
BLOOD (2002)
Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells: A model for immunotherapy
G Dotti et al.
EXPERIMENTAL HEMATOLOGY (2001)
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
DF Stojdl et al.
NATURE MEDICINE (2000)
Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma
JD Robertson et al.
BRITISH JOURNAL OF CANCER (2000)
Reovirus as a novel oncolytic agent
KL Norman et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells
AW Tong et al.
LEUKEMIA & LYMPHOMA (2000)
Share Paper
